CurrentAlliance HealthPolicy 9E

Off‑label Antipsychotic Safety Monitoring in Beneficiaries 18 and Older

Defines safety monitoring requirements and coverage stance for NC Medicaid beneficiaries age 18 and older who are prescribed antipsychotic medications used outside FDA‑approved indications or dosing, focusing on metabolic and neurologic side effect monitoring.

Policy Summary

PayerAlliance Health

PolicyOff‑label Antipsychotic Safety Monitoring in Beneficiaries 18 and Older

Policy CodePolicy 9E

Change TypeNo material change

Effective Date

Next Review Date

Key ActionPrescribers must input required beneficiary and safety monitoring data into the prescriber registry/monitoring portal and document baseline and interval measures (BMI, BP, glucose, lipids, CBC, ECG) when antipsychotics are used off‑label.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

18+beneficiary age group covered

BMI, BP, glucose, lipids, CBC, ECGrecommended monitoring

2+ agentspolypharmacy threshold

9Epolicy id

365 daysFDA-compliant bypass

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Off‑Label Antipsychotic Use

General coverage when medically necessary

Medicaid covers the procedure, product, or service when medically necessary and the following are met:

All conditions: a) the procedure, product, or service is individualized, specific, and consistent with symptoms or confirmed diagnosis of the illness or injury under treatment, and not in excess of the beneficiary's needs; b) the procedure, product, or service can be safely furnished, and no equally effective and more conservative or less costly treatment is available statewide; c) the procedure, product, or service is furnished in a manner not primarily intended for the convenience of the beneficiary, the beneficiary's caretaker, or the provider.

Supported by section 3.1

Safety monitoring trigger

Monitoring requirement applies when antipsychotic use is off‑label:

Monitoring trigger: Safety monitoring with documentation is required when an antipsychotic medication is used without indications and dosage levels approved by the FDA; monitoring shall target metabolic and neurologic side effects.

Supported by section 1.0

Triggers for registration/prior authorization and safety documentation

Registration/prior authorization and safety documentation are required when ANY of the following are present for beneficiaries age 18 and older:

PA/Registry triggers: a) Antipsychotic prescribed for an indication not approved by the FDA; b) Antipsychotic prescribed at a dosage different from FDA-approved dosing for that indication for a beneficiary 18 years of age and older; c) Prescribed antipsychotic results in concomitant use of two or more antipsychotics (intraclass polypharmacy).see intraclass polypharmacy definition (60-calendar day)

These triggers may prompt registration or prior authorization by NC Medicaid.

PA/Registration Exemptions

Beneficiaries with any of the following diagnoses are exempt from the registration or PA requirements:

Exempt diagnoses: Schizophrenia; Schizophreniform disorder; Schizoaffective disorder; Delusional disorder; Brief psychotic disorder; Shared psychotic disorder; Psychotic disorder Not Otherwise Specified (NOS); Bipolar disorder; Major depressive disorder with psychotic features; Treatment resistant depression (antipsychotic use for TRD is adjunctive only); Tourette syndrome; Other psychoses.

Pharmacist may override PA at point of sale if prescriber handwriting 'Meets PA Criteria' on prescription or entering it in e-prescription comments.

Bypass of documentation when FDA guidelines met

When FDA-approved guidelines are met for a beneficiary:

Bypass documentation: Further safety documentation will not be required by the provider for up to 365 days on a beneficiary-specific basis.365 days

Systems will be built to assure beneficiaries can obtain medications as prescribed.

Required safety monitoring parameters

Safety monitoring parameters to be collected at baseline and at recommended intervals:

Monitoring measures: Body Mass Index (BMI) percentile; blood pressure; glucose; lipid panel; complete blood count (CBC); electrocardiogram (ECG).baseline and at recommended frequencies per APA and accepted practice standards

Parameters based on APA and evidence-based sources.

Claims and provider compliance

Coverage and claims handling are governed by compliance with NC Medicaid policies and specified billing guidance.

Provider compliance requirements: Providers must comply with all applicable agreements, federal, state and local laws and regulations including HIPAA and record retention requirements, and all NC Medicaid clinical coverage policies, guidelines, provider manuals, implementation updates, and bulletins published by CMS, DHHS, DHHS divisions or fiscal contractors.

Supported by policy compliance section.

Claims submission method: Prescription drug claims must be submitted via online real-time point-of-sale using current NCPDP standards; institutional claims billed per National Uniform Billing Guidelines.

Refer to Attachment A for claims-related information.

Billing unit determination: Billing units for drugs are determined by the National Drug Code (NDC).

Refer to billing unit guidance.

Section 3.2.1 contains no additional, specialty-specific coverage criteria for this attachment. The document states None Apply for these specific covered criteria, so no extra covered-condition items are listed under that subsection.

Services are not covered when any of the general exclusion conditions in Section 4.1 are present: the beneficiary fails the eligibility requirements in Section 2.0; the beneficiary does not meet the criteria in Section 3.0; the service duplicates another provider's procedure/product/service; or the procedure/product/service is experimental, investigational, or part of a clinical trial.

Section 4.2.1 lists specialty-specific exclusions and indicates None Apply — there are no additional, itemized specific criteria that are explicitly excluded by this attachment.

For this attachment, ICD-10-CM and PCS coding is stated as Does not apply. Claims should follow the specified claim-type and billing guidance rather than ICD-10-CM/PCS coding within this document.

General medical necessity requirements in Section 3.1 apply: services are covered only when medically necessary and when they are individualized and consistent with the beneficiary's symptoms or confirmed diagnosis, can be safely furnished with no equally effective, more conservative, or less costly statewide alternative, and are not furnished primarily for convenience.

The policy explicitly excludes coverage when the procedure, product, or service is experimental, investigational, or part of a clinical trial. Such uses are listed among the general non-coverage triggers and may lead to claim denial.

Coding, Billing Units, and Claim Standards

Coding sections referencedmixed

No codes listed

Billing unit codingNDC

NDC	National Drug Code determines billing units

inv-17: Cross-titration window for polypharmacy

Cross-titration window60-calendar day window for intraclass polypharmacy (allows cross-titration when converting agents)

Intraclass polypharmacy thresholdCombination therapy defined as two or more antipsychotic agents outside the 60-calendar day cross-titration window

Trigger for safety documentationConcurrent use meeting intraclass polypharmacy definition requires safety monitoring documentation for point-of-sale claim processing

inv-18: ICD-10-CM/PCS applicability — does not apply

ICD-10-CM/PCS applicabilityDoes not apply for this attachment's scope

Claim coding note

Provider Responsibilities, Documentation, and Prior Authorization

Prior Authorization

EPSDT and Prior Approval for <21

Prior Authorization remains required for beneficiaries under age 21 when applicable. EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) rules do not eliminate prior approval requirements; refer to NCTracks Provider Claims and Billing Assistance Guide and the NC Medicaid EPSDT provider page for details.

Verify EPSDT and prior approval requirements at point of service
NCTracks Provider Claims and Billing Assistance Guide: https://www.nctracks.nc.gov/content/public/providers/providermanuals.html
EPSDT provider page: https://medicaid.ncdhhs.gov/

Prior Authorization

Registration / Prior Authorization for off‑label dosing or polypharmacy

NC Medicaid may require prescribers to register (or obtain prior authorization) when antipsychotic use for beneficiaries age 18+ meets any of the listed conditions. This registration/PA ensures the prescriber documents required safety monitoring.

Triggers for registration/PA: off‑label indication; dosing differing from FDA‑approved dosage for that indication; intraclass polypharmacy (two or more antipsychotics outside a 60‑day cross‑titration window)

Antipsychotic Medication Safety Monitoring

Antipsychotic medication safety monitoring — top-level monitoring node

Monitoring focus: Safety monitoring for off‑label antipsychotic use should target metabolic and neurologic side effects.

Section 1.0

Background and Scope

This policy addresses safety monitoring for NC Medicaid beneficiaries age 18 and older who are prescribed antipsychotic agents used off‑label. Monitoring is intended to detect metabolic and neurologic adverse effects and requires documentation of baseline and interval parameters per the policy. The policy scope emphasizes that monitoring is required when antipsychotic use is outside FDA‑approved indications or dosing, and it directs providers to collect recommended measures (for example, BMI, blood pressure, glucose, lipid panel, CBC, and ECG) and to follow registry and documentation procedures described in the authorization section.

Definitions and Key Terms

inv-32: Definitions — 'None Apply' for section 1.1

Section 1.1 definitionsNone Apply.

ImplicationNo specific term definitions are provided in section 1.1 of this policy attachment

ReferenceSee full policy text for contextual definitions elsewhere if needed

inv-33: Intraclass polypharmacy definition / combination therapy note

Intraclass polypharmacy definitionCombination therapy with two or more agents outside of a 60-calendar day window allowing for cross-titration when converting agents

Policy consequenceUse meeting this definition triggers required safety monitoring documentation for point-of-sale processing

Policy Summary

PayerAlliance Health

PolicyOff‑label Antipsychotic Safety Monitoring in Beneficiaries 18 and Older

Policy CodePolicy 9E

Change TypeNo material change

Effective Date

Next Review Date

SourceLink

On This Page

All claims must comply with National Coding Guidelines even though ICD-10-CM/PCS does not apply to this attachment

Institutional claims guidanceUnless directed otherwise, institutional claims must be billed per National Uniform Billing Guidelines

Exemptions: schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder NOS, bipolar disorder, major depressive disorder with psychotic features, treatment‑resistant depression (antipsychotic use adjunctive only), Tourette syndrome, other psychoses

Pharmacist may override PA at point of sale if prescriber hand‑writes or enters: 'Meets PA Criteria.'

Documentation Required

Eligibility Verification and Restrictions

Providers must verify Medicaid eligibility each time a service is rendered. Eligibility category may impose service restrictions that render a beneficiary ineligible for this service. Outpatient pharmacy services are available only to eligible beneficiaries.

Verify beneficiary eligibility at point of service/point of sale
Be aware eligibility category restrictions may block coverage and lead to claim denial

Documentation Required

Safety Monitoring Documentation and Registry Entry

Requests that trigger registration/PA require the prescriber to document safety monitoring in the designated monitoring portal/registry. Monitoring documentation is required for: antipsychotic prescribed without an FDA‑approved diagnosis; antipsychotic prescribed at a dose differing from FDA‑approved dosing; intraclass polypharmacy.

Prescriber must input required data elements for each affected beneficiary into the monitoring portal/registry
Safety monitoring targets metabolic and neurologic side effects (e.g., BMI, blood pressure, glucose, lipids, CBC, ECG) and must include baseline and follow‑up measurements at recommended intervals
Intraclass polypharmacy defined as two or more agents outside a 60‑calendar day window allowing for cross‑titration

Note

General Coverage Conditions (Medical Necessity and Conservative Therapy)

Coverage is limited to services that are medically necessary and meet general coverage conditions. The service must be individualized, consistent with the beneficiary's diagnosis or symptoms, safely furnished, not in excess of need, and not primarily for convenience. Conservative, equally effective, and less costly statewide options should be considered before use.

Medicaid covers services only when medically necessary and meeting all general criteria
Consider equally effective, more conservative, or less costly treatments statewide before approving antipsychotic use

Denial Risk

General Denial and Noncompliance Triggers

Claims may be denied for failure to meet eligibility or coverage criteria, missing safety monitoring documentation, or if the service is duplicative, experimental, or part of a clinical trial. Noncompliance with required registration/PA, portal/registry data entry, or NC Medicaid policies and agreements (including HIPAA and record retention) can trigger denials.

Denial triggers include: beneficiary not meeting Section 2.0 eligibility; not meeting Section 3.0 criteria; duplicate services; experimental/investigational or clinical trial services
Missing required safety monitoring documentation or registry entry for registration/PA cases
Failure to comply with NC Medicaid agreements, laws, HIPAA, record retention, or policy updates may result in denial

Documentation Required

Required Documentation and Policy Compliance

Providers must maintain documentation and comply with all applicable agreements, laws, NC Medicaid clinical coverage policies, provider manuals, and implementation updates. Records should be retained per applicable record‑retention requirements to demonstrate compliance if requested.

Adhere to HIPAA, federal/state/local laws, and record retention requirements
Follow NCTracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, clinical coverage policies, and reimbursement directions

Related triggersAlso considered when antipsychotic is prescribed off-label or at non‑FDA dosing for beneficiaries 18+

inv-34: Billing unit defined as National Drug Code (NDC)

Billing unitThe National Drug Code (NDC) determines the billing unit(s).

ApplicationBilling units for covered drugs are calculated based on the NDC as specified in Attachment A

Provider actionEnsure NDC is used to determine billing units on pharmacy claims

inv-35: Claim type — point-of-sale NCPDP / institutional billing per UB guidelines

Point-of-sale claimsOnline Real-Time Point of Sale using the current NCPDP standard is required for prescription drug claims.

Institutional claimsInstitutional claims must be billed according to the National Uniform Billing Guidelines unless directed otherwise.

Coding complianceAll claims must comply with National Coding Guidelines.